Nintedanib Demo (Nintedanib Esylate)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR and PDGFR—thereby inhibiting signaling pathways that drive fibroblast proliferation, migration, and extracellular matrix formation. This anti‑fibrotic and anti‑angiogenic action reduces scar tissue development in the lungs and can limit tumor blood‑vessel growth when combined with chemotherapy.

The dosage of Nintedanib is determined by the prescribing healthcare professional based on the specific indication, patient characteristics, and clinical response. Patients should follow the exact regimen provided by their physician and should not adjust the dose without medical advice.

The safety of Nintedanib in pregnancy and lactation has not been established. It is classified as having an unknown pregnancy category, and use is generally avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant. Breastfeeding mothers should consult their physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Nintedanib Demo. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative for idiopathic pulmonary fibrosis is pirfenidone, another antifibrotic agent. While both aim to slow disease progression, Nintedanib targets multiple tyrosine kinases and has a broader anti‑angiogenic profile, whereas pirfenidone works mainly through modulation of cytokine production. Choice of therapy depends on patient tolerance, comorbidities, and physician assessment.

Nintedanib Demo should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use. Do not store in a refrigerator or freezer.

Nintedanib is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets (or capsules, depending on the marketed form) are swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and should not crush or chew the medication.

Serious risks include elevated liver enzymes indicating possible hepatic injury, significant bleeding events especially when combined with anticoagulants, and cardiovascular complications such as hypertension or arterial thromboembolism. Patients should report any signs of liver dysfunction, unusual bleeding, or chest pain to their physician promptly.

Nintedanib is contraindicated in patients with severe hepatic impairment (Child‑Pugh C), those with known hypersensitivity to the drug, and individuals receiving strong CYP3A4 inhibitors that could markedly increase exposure. Caution is also advised for patients with active bleeding, uncontrolled hypertension, or recent major cardiovascular events.